Should You Invest in Ozempic Maker Novo Nordisk in 2026?

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.Is there a more popular health trend right now than GLP-1 agonist obesity drugs such as Ozempic? Probably not. Ironically, though, investing in Ozempic, or rather in its manufacturer, Novo Nordisk (NVO 0.63%), hasn't gone very well this year.Shares have fallen by 40% in 2025. Competition from Eli Lilly's similar drug, Zepbound, and from telehealth companies selling compounded versions of Ozempic ...